Everything below concerns NAD+ biosynthesis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-04. Numbers and descriptions here follow the published literature rather than marketing material.
Quality control for NMN materials typically includes identity, assay, impurity, and residual solvent tests. Certificates of analysis may report HPLC purity, water content, heavy metals, and microbial limits depending on the intended use. Because commercial NMN is sold as a research chemical or ingredient rather than a standardized drug in many jurisdictions, specifications can vary between suppliers. Independent verification can involve comparing retention time, mass spectrum, and NMR data against a reference standard. Open questions remain about how best to standardize purity claims and biological potency across different production methods.
Analytical identification of NMN usually combines chromatographic separation with mass spectrometric detection. High-performance liquid chromatography coupled to tandem mass spectrometry is common for quantifying NMN in biological matrices and finished materials. Because NMN and related nucleotides share similar masses and retention behavior, method development must resolve potential interferences such as nicotinamide riboside and NAD+. Ultraviolet detection at approximately 260 nm can be used for purity checks when concentrations are sufficient. Nuclear magnetic resonance spectroscopy provides structural confirmation and can distinguish anomeric forms.
Terminology around NMN can be confusing because several related compounds share the vitamin B3 family. Nicotinamide riboside is a nucleoside, whereas NMN is a nucleotide with a phosphate group, and NAD+ is a dinucleotide coenzyme rather than a simple precursor. Niacin and nicotinamide are also NAD+ precursors but follow different metabolic entry points. In commercial and scientific writing, NMN usually refers to beta-nicotinamide mononucleotide unless another form is specified. Consistent nomenclature helps distinguish chemical identity from proposed biological effects.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a pyridine nucleotide that consists of a nicotinamide ring, a ribose sugar, and a phosphate group. It is an intermediate in the salvage pathway for nicotinamide adenine dinucleotide, or NAD+, synthesis. In mammalian cells, the enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. Nicotinamide mononucleotide adenylyltransferases then convert NMN into NAD+. The core structure and enzymatic route are well established in biochemical literature.
| Property | Value | Notes |
|---|---|---|
| Common analytical method | HPLC-UV or LC-MS/MS | LC-MS/MS offers higher sensitivity for complex matrices. |
| Typical purity specification | ≥95% by HPLC | Values vary by supplier and product grade. |
| Storage temperature | −20 °C or lower | Desiccated and protected from light; avoid repeated warming. |
| Water solubility | Soluble | Aqueous solutions may be acidic and should be prepared fresh when possible. |
| Common synonyms | Nicotinamide mononucleotide; β-NMN | The β anomer is the naturally occurring form. |
Quality control for NMN materials typically includes appearance, assay, impurity profile, residual solvents, heavy metals, and microbial limits. A certificate of analysis summarizes specified tests, but the underlying methods and laboratory accreditation matter. Regulatory treatment varies by country; NMN is sold as a dietary supplement in some markets, while other jurisdictions restrict its use in foods or classify it differently. Independent verification can reduce risks of mislabeling or substitution. Questions remain about how product purity, storage history, and formulation affect delivered dose in humans.
Solid NMN is a polar, water-soluble nucleotide that can absorb moisture from air. Its phosphate ester is susceptible to hydrolysis, and degradation is faster in aqueous solution, under strongly acidic or alkaline conditions, and at elevated temperatures. For laboratory and commercial handling, the solid is typically kept desiccated, protected from light, and stored frozen. Repeated freeze-thaw cycles can introduce moisture and accelerate breakdown. Stability data for specific formulations should be generated rather than assumed from the parent compound.
Identity and purity of NMN are commonly assessed by liquid chromatography with ultraviolet detection or mass spectrometry. High-performance liquid chromatography can separate related impurities such as nicotinamide, nicotinamide riboside, and NAD+ depending on the method. Mass spectrometry provides molecular mass confirmation, while nuclear magnetic resonance spectroscopy helps establish structure and anomeric form. Quantitative assays often use calibration curves and, in biological samples, stable isotope-labeled internal standards. Method validation addresses specificity, linearity, accuracy, precision, and limits of detection.
Research interest in NMN increased after animal studies reported that oral or injected NMN can raise NAD+ levels in some tissues. How NMN is absorbed and distributed in humans is not fully established. Some evidence suggests extracellular NMN may be dephosphorylated to nicotinamide riboside before cellular uptake, while other studies propose specific transport routes. Direct human data on these mechanisms remain limited. Regulatory status also varies: in some countries NMN is treated as a dietary supplement, while elsewhere it is restricted or requires approval, and these differences affect labeling, sale, and research.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide found in the cells of many organisms. Its structure consists of a nicotinamide group linked to a ribose sugar that carries a phosphate group. NMN is an intermediate in the biosynthesis of nicotinamide adenine dinucleotide, or NAD+, a coenzyme involved in many metabolic reactions. The abbreviation usually refers to the beta anomer, though related forms can exist. In scientific literature, NMN is distinct from nicotinamide riboside, another NAD+ precursor.
In the NAD+ salvage pathway, the enzyme NAMPT converts nicotinamide and a phosphate-donor molecule into NMN. A second enzyme, NMNAT, then converts NMN into NAD+. Nicotinamide riboside can also enter this route after being converted to NMN by nicotinamide riboside kinases. Because NMN sits at a junction between precursor uptake and NAD+ formation, its cellular concentration is tightly linked to enzyme activity and tissue type. NAD+ participates in redox reactions, signaling, and DNA repair, and its levels decline with age in some animal models, though human evidence remains more limited and context-dependent.
Analytical identification of NMN commonly uses high-performance liquid chromatography with ultraviolet detection, liquid chromatography-mass spectrometry, and nuclear magnetic resonance spectroscopy; HPLC can estimate purity by peak area, while mass spectrometry confirms molecular mass and fragmentation. NMR provides structural confirmation. Because NMN is charged, ion-pairing reagents or hydrophilic interaction liquid chromatography columns can improve retention and peak shape. In biological samples, LC-MS/MS with stable isotope internal standards is often used to quantify NMN and related NAD+ metabolites. Method validation is important because matrix effects and rapid enzymatic interconversion can complicate measurements.
Quality control for NMN typically checks identity, assay purity, residual solvents, heavy metals, and microbial limits, depending on the intended use and market. A certificate of analysis may report appearance, solubility, water content, and storage recommendations. Independent verification can compare chromatographic retention time and mass spectrum against a certified reference standard. Regulatory expectations differ between research chemicals, dietary ingredients, and pharmaceutical products. Impurity profiles and stability data are often requested for product approval, and open questions remain about how best to standardize NMN measurements across laboratories.
NMN is a polar, water-soluble nucleotide. In solid form it is usually a white to off-white powder. The compound is sensitive to heat, light, moisture, and extremes of pH, and aqueous solutions tend to degrade faster than dry material. Recommended storage for research samples is typically -20 °C or below in a sealed, desiccated container protected from light. Repeated freeze-thaw cycles should be avoided, and these handling practices help maintain identity and purity during laboratory use.
Nicotinamide mononucleotide, abbreviated NMN, is a nucleotide composed of nicotinamide, ribose, and phosphate. Its structure links nicotinamide to D-ribose 5-phosphate through a glycosidic bond, placing it in the pyridine nucleotide family. The compound exists in alpha and beta anomeric forms, and the beta form is the one used in NAD+ biosynthesis. NMN is not a protein or a hormone; it is a small water-soluble molecule that occurs in living cells as a metabolic intermediate.
Natural sources of NMN include mammals, plants, and microorganisms, where it functions as an intermediate in NAD+ salvage and biosynthesis pathways. In mammals, the enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. NMN is then converted to NAD+ by nicotinamide mononucleotide adenylyltransferase. Some foods contain measurable NMN, but reported amounts vary widely by species, tissue, and analytical method. The extent to which dietary NMN contributes to cellular NAD+ pools remains an open research question.
== Biosynthesis == Echinomycin is a bis-intercalator peptide and is biosynthesized by a unique nonribosomal peptide synthetase (NRPS). Echinomycin is isolated from various bacteria such as Streptomyces lasalienis. It belongs to a family of quinoxaline antibiotics. There is great interest in this group of compounds because they have very potent antibacterial, anticancer, and antiviral activities. The biosynthesis of echinomycin starts with molecule QC. L-tryptophan is the precursor for QC and its biosynthesis parallels the first stage of nikkomycin biosynthesis. After QC is biosynthesized, the adenylation domain-containing Ecm1 activates and transfers QC to FabC using the fatty acid biosynthesis acyl carrier protein (ACP). The first module, Ecm6 accepts the QC-SFabC as the starter unit. Emc7 contains a terminal thioesterase domain which allows the peptide to dimerize and then release. This cyclized product then goes on to Ecm17, an oxidoreductase, creating a disulfide bond. The last step in this biosynthesis transforms the disulfide bond into a thioacetal bridge. This transformation takes place within Ecm18, a S-adenosyl-L-methionine (SAM)-dependent methyltransferase. The mechanism is proposed to proceed through two steps. Initially Emc18 transfers the activated methyl group from SAM to one of the sulfur atoms in the disulfide bond. Secondly deprotonation of the alpha proton to the tertiary sulfonium cation promotes the rearrangement for the formation of the thioacetal bond.
=== Selected publications === Foster Dee Snell, Clifford L Hilton, Leslie S Ettre, Encyclopedia of Industrial Chemical Analysis (John Wiley & Sons, 1966–1974), 20 volume set. L.S. Ettre and J.E. Purcell, Advances in Chromatography, Vol. 10, J.C. Giddings and R.A. Keller, Eds. (M. Dekker, Inc., New York, 1974) L. S. Ettre, "Farewell to 'Milestones in Chromatography'," LC/GC North America April, 2008. Leslie S. Ettre; Albert Zlatkis (2011). 75 Years of Chromatography: A Historical Dialogue. Elsevier. ISBN 978-0-08-085817-3. Chromatography: the Separation Technique of the 20th Century, Chromatographia Vol. 51, No. 1/2, January 2000, pp. 7–17 (Centennial Review).
=== Genomics === Notable P. fluorescens strains SBW25, Pf-5 and PfO-1 have been sequenced, among others. A comparative genomic study (in 2020) analyzed 494 complete genomes from the entire Pseudomonas genus, with 25 of them being annotated as P. fluorescens. The phylogenomic analysis clearly showed that the 25 strains annotated as P. fluorescens did not form a monophyletic group. In addition, their Average Nucleotide Identities did not fulfil the criteria of a species, since they were very diverse. It was concluded that P. fluorescens is not a species in the strict sense, but should be considered as a wider evolutionary group, or a species complex, that includes within it other species too. This finding is in accordance with previous analyses of 107 Pseudomonas species, using four core 'housekeeping' genes, that consider P. fluorescens as a relaxed species complex. The P. fluorescens relaxed evolutionary group that was defined by Nikolaidis et al. on the basis of the genus phylogenomic tree, comprised 96 genomes and displayed high levels of phylogenetic heterogeneity. It comprised many species, such as Pseudomonas corrugata, Pseudomonas brassicacearum, Pseudomonas frederiksbergensis, Pseudomonas mandelii, Pseudomonas kribbensis, Pseudomonas koreensis, Pseudomonas mucidolens, Pseudomonas veronii, Pseudomonas antarctica, Pseudomonas azotoformans, Pseudomonas trivialis, Pseudomonas lurida, Pseudomonas poae, Pseudomonas libanensis, Pseudomonas synxantha, and Pseudomonas orientalis. The core proteome of the P. fluorescens group comprised 1396 proteins.
Both types of diabetes, if untreated, result in too much glucose remaining in the blood (hyperglycemia) and many of the same complications. Also, too much insulin and/or exercise without enough corresponding food intake in diabetics can result in low blood sugar (hypoglycemia).
A total synthesis of progesterone was reported in 1971 by William S. Johnson. The synthesis begins with reacting the phosphonium salt 7 with phenyl lithium to produce the phosphonium ylide 8. The ylide 8 is reacted with an aldehyde to produce the alkene 9. The ketal protecting groups of 9 are hydrolyzed to produce the diketone 10, which in turn is cyclized to form the cyclopentenone 11. The ketone of 11 is reacted with methyl lithium to yield the tertiary alcohol 12, which in turn is treated with acid to produce the tertiary cation 13. The key step of the synthesis is the π-cation cyclization of 13 in which the B-, C-, and D-rings of the steroid are simultaneously formed to produce 14. This step resembles the cationic cyclization reaction used in the biosynthesis of steroids and hence is referred to as biomimetic. In the next step the enol orthoester is hydrolyzed to produce the ketone 15. The cyclopentene A-ring is then opened by oxidizing with ozone to produce 16. Finally, the diketone 17 undergoes an intramolecular aldol condensation by treating with aqueous potassium hydroxide to produce progesterone.
Sources: en.wikipedia.org
(AstraZeneca, 2014) Peginesatide (Omontys) – once-monthly medication to treat anemia associated with chronic kidney disease in adult patients on dialysis (Affymax/Takeda Pharmaceuticals, 2012) Pegloticase (Krystexxa) – PEGylated uricase for the treatment of gout (Savient, 2010) Certolizumab pegol (Cimzia) – monoclonal antibody for treatment of moderate to severe rheumatoid arthritis and Crohn's disease, an inflammatory gastrointestinal disorder (Nektar/UCB Pharma, 2008) Methoxy polyethylene glycol-epoetin beta (Mircera) – PEGylated form of erythropoietin to combat anemia associated with chronic kidney disease (Roche, 2007) Pegaptanib (Macugen) – used to treat neovascular age-related macular degeneration (Pfizer, 2004) Pegfilgrastim (Neulasta) – PEGylated recombinant methionyl human granulocyte colony-stimulating factor for severe cancer chemotherapy-induced neutropenia (Amgen, 2002) Pegvisomant (Somavert) – PEG-human growth hormone mutein receptor antagonist for treatment of Acromegaly (Pfizer, 2002) Peginterferon alfa-2a (Pegasys) – PEGylated interferon alpha for use in the treatment of chronic hepatitis C and hepatitis B (Hoffmann-La Roche, 2002) Peginterferon alfa-2b (PegIntron) – PEGylated interferon alpha for use in the treatment of chronic hepatitis C and hepatitis B (Schering-Plough/Enzon, 2000) Doxorubicin HCl liposome (Doxil/Caelyx) – PEGylated liposome containing doxorubicin for the treatment of cancer (Alza, 1995) Pegaspargase (Oncaspar) – PEGylated L-asparaginase for the treatment of acute lymphoblastic leukemia in patients who are hypersensitive to the native unmodified form of L-asparaginase (Enzon, 1994). This drug was recently approved for front line use. Pegademase bovine (Adagen) – PEG-adenosine deaminase for the treatment of severe combined immunodeficiency disease (SCID) (Enzon, 1990)
== Growth == The optimal growth temperature range for B. cereus is 30–40 °C (86–104 °F). At 30 °C , a population of B. cereus can double in as little as 20 minutes or as long as 3 hours, depending on the food product. Spores of B. cereus are not metabolically active, but can rapidly become active and begin replicating once they encounter adequate growth conditions.
Collins correctly identified a photo of Elton John, however Hasselhoff mistook a photo of Debbie Harry for Cyndi Lauper and they were eliminated in the first round with a score of 147. In April 2025, Collins attended the "24 Hour Piano-thon" at Liverpool Street Station which was in promotion of the third series of the Channel 4 music competition show The Piano. Collins played a rendition of Chopsticks on the piano, before performing I Wanna Dance with Somebody (Who Loves Me) by Whitney Houston alongside the Keynotes Choir. In March 2026, after attending the Cheltenham Festival the previous year and not winning anything, Collins returned to the event and ultimately won £20,000 throughout the day, which included £5,000 on one bet after she bet on a horse who won its race with odds of 9/1. In an interview during the ITV Racing coverage, Collins said attending the event had "ignited a fire in her" and encouraged other people, especially women to attend, describing it as "not just a man's sport" and added that she'd probably earn enough money at next year's event to "buy the Cheltenham Racecourse". In April 2026, Collins returned to I'm a Celebrity, 11 years after her original appearance, to take part in the second series of the "All Stars" spin-off I'm a Celebrity... South Africa, which was filmed in September 2025 and featured campmates from previous series.
=== Less common === Confusion Irritability and aggression Psychomotor agitation Lack of motivation Increased libido Loss of libido Impaired motor function Impaired coordination Impaired balance Dizziness Cognitive impairments Hallucinations. Short-term memory loss Anterograde amnesia (common with higher doses) Some users report hangover-like symptoms of drowsiness, headaches, sluggishness, and irritability upon waking up if the medication was taken before sleep. This is likely the result of the medication's long half-life, which continues to affect the user after waking up. While benzodiazepines induce sleep, they tend to reduce the quality of sleep by suppressing or disrupting REM sleep. After regular use, rebound insomnia may occur when discontinuing clonazepam. Benzodiazepines may cause or worsen depression.
== Adverse effects == The US Food and Drug Administration prescribing information contains a boxed warning for embryo-fetal toxicity. The most common adverse reactions include diarrhea, infusion-related reactions, abdominal pain, and fatigue.
Sources: en.wikipedia.org
Common methods include HPLC with ultraviolet detection and LC-MS/MS. These techniques separate NMN from related nucleotides and quantify it by retention time and mass-to-charge ratio.
Low temperature and low moisture slow hydrolysis and other degradation reactions. Desiccants and sealed containers reduce exposure to water vapor and oxygen.
It typically reports identity, purity, water content, and selected impurities. The exact panel depends on the supplier, product grade, and intended application.
NMN stands for nicotinamide mononucleotide. It is a naturally occurring nucleotide intermediate in NAD+ biosynthesis.